Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:INVA NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.07-0.6%$9.16$6.00▼$11.31$2.30B0.575.12 million shs2.12 million shsCLDXCelldex Therapeutics$31.98+1.0%$32.06$18.55▼$35.79$2.51B0.98902,006 shs222,962 shsINVAInnoviva$21.77-1.6%$22.92$16.52▼$25.15$1.61B0.38727,919 shs432,568 shsMNKDMannKind$3.61+1.5%$2.83$2.23▼$6.51$1.11B1.045.61 million shs3.24 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+7.67%+4.35%+2.47%+15.44%-15.48%CLDXCelldex Therapeutics+2.59%+2.43%-5.97%+3.30%+60.01%INVAInnoviva-2.43%-0.49%-5.27%-5.99%+15.56%MNKDMannKind+0.57%+9.23%+34.98%+9.57%-15.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.07-0.6%$9.16$6.00▼$11.31$2.30B0.575.12 million shs2.12 million shsCLDXCelldex Therapeutics$31.98+1.0%$32.06$18.55▼$35.79$2.51B0.98902,006 shs222,962 shsINVAInnoviva$21.77-1.6%$22.92$16.52▼$25.15$1.61B0.38727,919 shs432,568 shsMNKDMannKind$3.61+1.5%$2.83$2.23▼$6.51$1.11B1.045.61 million shs3.24 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+7.67%+4.35%+2.47%+15.44%-15.48%CLDXCelldex Therapeutics+2.59%+2.43%-5.97%+3.30%+60.01%INVAInnoviva-2.43%-0.49%-5.27%-5.99%+15.56%MNKDMannKind+0.57%+9.23%+34.98%+9.57%-15.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$20.70126.97% UpsideCLDXCelldex Therapeutics 2.80Moderate Buy$49.7857.28% UpsideINVAInnoviva 2.57Moderate Buy$36.2063.58% UpsideMNKDMannKind 2.60Moderate Buy$8.84149.12% UpsideCurrent Analyst Ratings BreakdownLatest MNKD, BCRX, CLDX, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.005/13/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $54.005/8/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $48.005/7/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $10.005/7/2026MNKDMannKind HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.005/7/2026BCRXBioCryst Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$25.00 ➝ $28.005/7/2026BCRXBioCryst Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$22.00 ➝ $21.005/7/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $42.005/7/2026MNKDMannKind Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$3.50 ➝ $4.755/7/2026MNKDMannKind MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.005/6/2026BCRXBioCryst Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.00(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.65$1.33 per share6.84($2.18) per share-4.18CLDXCelldex Therapeutics$1.54M1,613.12N/AN/A$5.81 per share5.45INVAInnoviva$411.33M3.97$4.91 per share4.51$18.18 per share1.22MNKDMannKind$348.97M3.14$0.06 per share57.05($0.19) per share-18.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A28.50N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)INVAInnoviva$271.17M$6.013.688.85N/A119.89%33.33%22.67%8/5/2026 (Estimated)MNKDMannKind$5.86M-$0.07N/A23.67N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)Latest MNKD, BCRX, CLDX, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 million5/6/2026Q1 2026MNKDMannKind-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92INVAInnoviva0.1921.1320.07MNKDMannKindN/A1.871.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/AINVAInnoviva99.12%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals5.10%CLDXCelldex Therapeutics5.20%INVAInnoviva2.01%MNKDMannKind2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million241.20 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableINVAInnoviva10073.81 million72.33 millionOptionableMNKDMannKind400308.95 million300.92 millionOptionableMNKD, CLDX, BCRX, and INVA HeadlinesRecent News About These CompaniesMannKind Released From Major Afrezza Trial ObligationMay 28 at 9:11 AM | tipranks.comMannKind to Present at Jefferies Global Healthcare ConferenceMay 27 at 4:00 PM | globenewswire.comMannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) SystemsMay 27 at 9:05 AM | globenewswire.comMannKind Shareholders Reaffirm Board, Pay, and Auditor RolesMay 22, 2026 | tipranks.comMannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2MMay 18, 2026 | insidermonkey.comHC Wainwright Brokers Raise Earnings Estimates for MannKindMay 18, 2026 | americanbankingnews.comFY2026 EPS Estimates for MannKind Increased by HC WainwrightMay 18, 2026 | marketbeat.comSteven Binder Sells 16,940 Shares of MannKind (NASDAQ:MNKD) StockMay 14, 2026 | insidertrades.comWells Fargo Raises its Price Target on MannKind (MNKD) to $10May 13, 2026 | insidermonkey.comH.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price TargetsMay 11, 2026 | insidermonkey.comWall Street Zen Downgrades MannKind (NASDAQ:MNKD) to SellMay 9, 2026 | marketbeat.comMannKind: Q1 Earnings SnapshotMay 8, 2026 | stamfordadvocate.comSMannKind drops after Q1 missMay 8, 2026 | seekingalpha.comMannKind targets $110M-$120M 2026 FUROSCIX revenue as it nears May 29 and July 26 PDUFA catalystsMay 8, 2026 | msn.comMannKind Leans Into Growth Amid Earnings VolatilityMay 7, 2026 | tipranks.comMannKind (NASDAQ:MNKD) Price Target Raised to $4.75May 7, 2026 | marketbeat.comMannKind: It's ComplicatedMay 7, 2026 | seekingalpha.comMannKind (NASDAQ:MNKD) Given New $7.00 Price Target at MizuhoMay 7, 2026 | marketbeat.comMannKind Corporation 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comMannKind (NASDAQ:MNKD) Announces Earnings Results, Misses Estimates By $0.03 EPSMay 6, 2026 | marketbeat.comMannKind Q1 Earnings Call HighlightsMay 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNKD, CLDX, BCRX, and INVA Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$9.06 -0.06 (-0.60%) As of 02:41 PM Eastern This is a fair market value price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$31.98 +0.33 (+1.03%) As of 02:41 PM Eastern This is a fair market value price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$21.76 -0.37 (-1.65%) As of 02:41 PM Eastern This is a fair market value price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$3.60 +0.06 (+1.55%) As of 02:40 PM Eastern This is a fair market value price provided by Massive. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas IREN Is Flipping the Switch from Bitcoin to AI This Quantum Computing Stock May Be Closer to a Breakout Than You Think Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It If the Market Rally Stalls, This ETF Can Insulate Portfolios RTX Is Set to Revolutionize Munitions Manufacturing Is Co-Diagnostics National Security’s Next Diagnostic Pick? Semtech’s Explosive Rally May Only Be Getting Started The Food Delivery War Just Entered Its Final Phase Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
